



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/764,379	01/23/2004	Jack Henkin	6356.US.C1	1701

23492 7590 02/06/2006

ROBERT DEBERARDINE
ABBOTT LABORATORIES
100 ABBOTT PARK ROAD
DEPT. 377/AP6A
ABBOTT PARK, IL 60064-6008

EXAMINER

LUKTON, DAVID

ART UNIT PAPER NUMBER

1654

DATE MAILED: 02/06/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/764,379

Applicant(s)

HENKIN ET AL.

Examiner

David Lukton

Art Unit

1654

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 20 January 2006.
2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-17 is/are pending in the application.
4a) Of the above claim(s) 1-14 and 16 is/are withdrawn from consideration.
5) ☐ Claim(s) _____ is/are allowed.
6) ☒ Claim(s) 15 and 17 is/are rejected.
7) ☐ Claim(s) _____ is/are objected to.
8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☒ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____.
4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____.
5) ☐ Notice of Informal Patent Application (PTO-152)
6) ☐ Other: _____.

Applicant's election of a disease to be treated is acknowledged, i.e., treatment of cancer. Claims 15 and 17 are examined in this Office action; claims 1-14 and 16 are withdrawn from consideration.



Claim 17 is rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claim 10 of U.S. Patent No. 6774211. Although the conflicting claims are not identical, they are not patentably distinct from each other. There is overlap of the genus of compounds underlying the respective methods.

The obviousness-type double patenting rejection is a judicially established doctrine based upon public policy and is primarily intended to prevent prolongation of the patent term by prohibiting claims in a second patent not patentably distinct from claims in a first patent.

In re Vogel, 164 USPQ 619 (CCPA 1970). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(b) would overcome an actual or provisional rejection on this ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.78(d)



The following is a quotation of the first paragraph of 35 U.S.C. §112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it in such full, clear, concise and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claim 15 is rejected under 35 U.S.C. 112, first paragraph, as containing subject matter

which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

As presented in table 2 (page 40), the compound of example 1 is effective to inhibit neovascularization in rat corneas. Also shown (pages 182-183) is that several of the claimed compounds can inhibit microvascular endothelial migration *in vitro*. It is stipulated that inhibition of angiogenesis will occur both *in vitro* and *in vivo*. But applicants are extrapolating from these *in vitro* results to treatment of various diseases such as cancer, arthritis, pathological angiogenesis resulting from infection, macular degeneration, and diabetic retinopathy. Perhaps it is true that under carefully controlled laboratory conditions, using a certain species of rat, and using a specific tumor cell line, some reduction of tumor volumes has been observed using one or two compounds other than those claimed. However, structure/function relationships are "unpredictable" where angiogenesis is concerned, i.e., inhibition of angiogenesis is a question of degree. As stated in *Ex parte Forman* (230 USPQ 546, 1986). and subsequently affirmed in *In re Wands* (8 USPQ2d 1400, Fed. Cir., 1988) the factors to consider in evaluating the need (or absence of need) for "undue experimentation" are the following: quantity of experimentation necessary, amount of direction or guidance presented, presence or absence of working examples, nature of the invention, state of the prior art, relative skill of those in that art, predictability or unpredictability of the art, and breadth of the claims.

It is stipulated that inhibition of angiogenesis will occur *in vivo*, and that inhibition of tumor cell proliferation will also occur *in vivo*. However, such inhibition is not necessarily predictive of therapeutic success. If the degree of inhibition is insufficient, an improvement in the patient's condition will not be realized. In addition, there is the matter of bioavailability/pharmacokinetics, and xenobiotic metabolism. These parameters will all change (in unpredictable ways) with structure of the compounds. Consider also the following:

- Nicosia (*American Journal of Pathology* 138 (4) 829-33, 1991) discloses that the peptide GRGDS is effective to inhibit angiogenesis, but that if the aspartic acid side chain is extended by just one methylene group, loss of activity results. Thus, the conclusion is that structure/activity relationships are "unpredictable" where angiogenesis inhibition is concerned.
- Belo (*Inflammation* 25 (2) 91-6, 2001) discloses that thalidomide inhibited angiogenesis in mice, but failed to inhibit tumor growth in the same mouse strain.
- Mundhenke, "Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin" (*Clinical Cancer Research* 7 (11) 3366-74, 2001) disclosed the results of a phase I clinical trial with endostatin, which is an angiogenesis inhibitor. The result is that the endostatin was not particularly effective in treating cancer patients.
- Pignatelli (*Human Pathology* 23 (10) 1159-66, 1992) discloses that in breast carcinomas, expression of integrins is downregulated. This tends to suggest that if one makes "static" assumptions about the level of expression of integrins on tumor cells, an "unpredictable" outcome is likely.

Thus, one can conclude even if angiogenesis can be achieved by a given compound "X",

reduction of tumor volumes by the compound "X" is "unpredictable".

Furthermore, even if, at some point in the future, applicants could demonstrate that there is one specific form of cancer that will yield to the disclosed compounds, it would not follow therefrom that all forms of cancer can be successfully treated. The term "cancer" encompasses a variety of diseases, including the following: breast cancer, prostate cancer, lung cancer, colon cancer, rectal cancer, bladder cancer, Non-Hodgkin Lymphoma, melanomas of the skin, cancer of the Kidney and Renal Pelvis, pancreatic cancer, oral cancer, esophageal cancer, ovarian cancer, thyroid cancer, stomach cancer, brain cancer, multiple myeloma, liver and intrahepatic bile duct cancer, acute myeloid leukemia, chronic lymphocytic leukemia, Hodgkin's Lymphoma, testicular cancer, intestinal cancer, chronic myeloid leukemia, acute lymphocytic leukemia, cancer of the vulva, gallbladder cancer, malignant mesothelioma, bone cancer, joint cancer, cancer of the hypopharynx, cancer of the eye, cancer of the nose, cancer of the ureter, cancer of the peritoneum, gastrointestinal carcinoid tumors, bladder cancer, melanoma, breast cancer, non-hodgkin's lymphoma, ovarian cancer, endometrial cancer, pancreatic cancer, kidney cancer (renal cell), prostate cancer, leukemia, non-melanoma cancer of the skin. Also included are sarcomas and carcinomas, such as the following: fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, ovarian

cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, retinoblastoma, leukemia, lymphoma, multiple myeloma, Waldenström's macroglobulinemia, and heavy chain disease. The oncologist of ordinary skill would not find persuasive the proposal that if an agent is effective to treat one form of cancer, it will be effective to treat all forms of cancer.

As for arthritis and psoriasis, applicants have not established that angiogenesis is a critical factor in the manifestations of these disorders; it is not established that if a compound is effective to inhibit angiogenesis, it will be effective to treat either one of these diseases.

In accordance with the following, "undue experimentation" would be required to practice the claimed invention.



Claims 15 and 17 are rejected under 35 U.S.C. §112 second paragraph, as being indefinite for

failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

- Each of claims 15 and 17 is dependent on a non-elected claim.
- Claim 15 is indefinite as to the intended diseases.
- Claim 1 recites that A₄ is an amino acyl residue of L or D configuration selected from, among other possibilities, D-alanyl. Is it the case that when alanine is present at this position in the peptide that it must be "D", or can it be "L"...?
- Claim 1 recites that A₄ can be "cystyl". Is this intended to be a moiety other than cysteinyl, and if so, what is the structure?
- Claim 1 recites that A₄ can be "D" or "L" glycyl. In what way are these two structures different?
- Claim 1 recites that A₅ is an amino acyl residue of L or D configuration selected from, among other possibilities, seryl and D-seryl. However, this constitutes a Markush group containing redundant members.
- Claim 1 recites that A₆ can be "tryptyl". Is this intended to be a moiety other than tryptophanyl, and if so, what is the structure?
- Claim 1 recites that A₆ is an amino acyl residue of L or D configuration selected from, among other possibilities, glutaminyl and D- glutaminyl. However, this constitutes a Markush group containing redundant members.



The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this action.

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claim 15 is rejected under 35 U.S.C. §102(b) as being anticipated by Low (USP 4395404)

Low discloses (col 2, line 30) the following peptide:

Q-A-G-E-S-N-A-K-T

This peptide falls within the scope of instant claim 1. Claim 15 is anticipated because no objective is recited; accordingly all objectives are encompassed.



Serial No. 10/764,379
Art Unit 1654

-9-

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David Lukton whose telephone number is 571-272-0952. The examiner can normally be reached Monday-Friday from 9:30 to 6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell, can be reached at (571)272-0974. The fax number for the organization where this application or proceeding is assigned is 571-273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 571-272-1600.



DAVID LUKTON
PATENT EXAMINER
GROUP 1800